Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $29.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Imunon in a research note on Thursday, December 19th.

Imunon Trading Up 7.6 %

Shares of Imunon stock opened at $0.96 on Friday. The company has a 50-day moving average of $0.85 and a two-hundred day moving average of $1.03. Imunon has a 12-month low of $0.48 and a 12-month high of $3.65. The stock has a market cap of $13.88 million, a PE ratio of -0.51 and a beta of 2.04.

Imunon (NASDAQ:IMNN) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.03. During the same period in the previous year, the company earned ($0.37) earnings per share. On average, sell-side analysts forecast that Imunon will post -1.68 EPS for the current fiscal year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.